Oncology Institute grants 27,108 RSUs to director

Hively Brad reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Hively Brad reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. reported that director Brad Hively received an equity grant of 27,108 shares of common stock on July 27, 2026, structured as restricted stock units (RSUs) at a stated price of $0.0000 per share. Each RSU entitles him to one share of common stock upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, subject to his continued service with the company through that date. Following this award, Hively directly holds 710,829 shares of Oncology Institute common stock.

Insider Trade Summary

Grant/Award: 27,108 shares

Grant/Award 1 txn

Insider Hively Brad

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	27,108	$0.00	$0.00

Holdings After Transaction: Common Stock — 710,829 shares (Direct)

Footnotes (1)

1. F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

Key Figures

RSUs Granted: 27,108 shares Post-transaction Holdings: 710,829 shares Grant Price: $0.0000 per share

3 metrics

RSUs Granted 27,108 shares Restricted stock units granted to director Brad Hively on July 27, 2026

Post-transaction Holdings 710,829 shares Total direct common stock holdings of Brad Hively after the RSU grant

Grant Price $0.0000 per share Stated price per share for the RSU award reported as a grant

Key Terms

restricted stock units (RSUs), vest in full, continued service

3 terms

restricted stock units (RSUs) financial

"Represents grant of restricted stock units (RSUs), each of which entitle"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vest in full financial

"The RSUs vest in full on the date of the Issuer's 2027 annual"

continued service financial

"subject to the Reporting Person's continued service with the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Brad Hively report in TOI’s latest Form 4?

Brad Hively reported an equity grant of 27,108 RSUs for Oncology Institute, Inc. common stock on July 27, 2026. Each RSU converts into one share upon settlement, increasing his direct holdings to 710,829 shares after the grant.

How many TOI shares did Brad Hively acquire through the RSU grant?

Brad Hively acquired 27,108 restricted stock units (RSUs), each representing one future share of Oncology Institute, Inc. common stock. The award was reported at a stated price of $0.0000 per share, indicating a compensation grant rather than an open-market purchase.

What is the vesting schedule for Brad Hively’s TOI RSU grant?

The 27,108 RSUs granted to Brad Hively vest in full on the date of Oncology Institute, Inc.’s 2027 annual meeting of stockholders. Vesting is conditioned on his continued service with the company through that meeting date.

What is Brad Hively’s TOI share ownership after this Form 4 transaction?

After the reported RSU grant, Brad Hively directly holds 710,829 shares of Oncology Institute, Inc. common stock. This figure reflects his total direct ownership immediately following the July 27, 2026 award as disclosed in the filing.

Was Brad Hively’s TOI RSU grant reported as part of a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, so the RSU grant is not identified as made pursuant to a Rule 10b5-1 plan. It is reported simply as a compensation-related equity award.

Did Brad Hively sell any TOI shares in this Form 4 filing?

No sales were reported; the Form 4 shows only an acquisition of 27,108 RSUs for Oncology Institute, Inc. common stock. The transaction code is “A”, described as a grant, award, or other acquisition, with no corresponding dispositions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 06:49 PM Accepted by SEC EDGAR 07/29/2026 - 06:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hively Brad

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		A(1)		27,108	A	$0.00	710,829	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Brad Hively	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)